Compare AbbVie Inc (ABBV) vs Bath & Body Works Inc (BBWI) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
AbbVie Inc vs Bath & Body Works Inc — how do they compare? AbbVie Inc trades at $253.73 (market cap $449.91B), while Bath & Body Works Inc trades at $19.44 (market cap $4.16B). The key difference: AbbVie Inc is far larger — about 108.2× Bath & Body Works Inc's market cap, and Bath & Body Works Inc pays the higher dividend (3.88%). Which is the better fit depends on your goals.
| ABBV | BBWI | |
|---|---|---|
Market Cap | $449.91B | $4.16B |
Sector | Health | Consumer Cyclical |
52-Week High | $261.07 | $33.65 |
52-Week Low | $184.85 | $14.85 |
Enterprise Value | $513.38B | $8.05B |
Dividend Yield | 2.72% | 3.88% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbbVie (ABBV) trades at $253.61, down 0.45% on the day, with strong technical momentum showing bullish moving averages and key support at $253. The company reported Q1 2026 EPS of $2.65, beating expectations, while revenue growth is supported by Skyrizi and Rinvoq offsetting Humira declines. Analysts maintain a bullish consensus with 68% buy ratings and a $266.33 price target, representing 5% upside potential.
The outlook remains positive with robust immunology portfolio performance and dividend growth, though risks include patent cliffs in the 2030s and competitive pressures. Current valuation metrics appear elevated with P/E at 124.83, requiring sustained earnings growth to justify premium multiples. The stock offers income appeal with consistent dividend payments while navigating portfolio transition.
BBWI trades at $20.62, down 6.1% over 24 hours, with a bullish technical signal from moving averages and neutral oscillators. The stock is valued attractively with a P/E of 6.23 and P/S of 0.62, while recent earnings beat expectations in Q1 2026. Revenue has declined over five years, but the company maintains strong cash flow and a new partnership with Ulta Beauty aims to expand reach.
The outlook is mixed: deep valuation discounts and strategic initiatives like the Ulta partnership offer upside, but persistent revenue declines and high debt pose risks. Analyst consensus is a $22.50 price target with no sell ratings, indicating cautious optimism for a turnaround if execution improves.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AbbVie Inc
AbbVie is a pharmaceutical company with a strong exposure to immunology and oncology. The firm's top drug, Humira, represents close to half of the company's current profits. The company was spun off from Abbott in early 2013. The recent acquisition of Allergan adds several new drugs in aesthetics and women's health.
Read more on ABBV →About Bath & Body Works Inc
Bath & Body Works is a specialty home fragrance and fragrant body care retailer operating under the Bath & Body Works, C.O. Bigelow, and White Barn brands. The company generates most of its business in North America, with less than 5% of sales from international markets in fiscal 2021. For fiscal 2021, 72% of sales stemmed from the brick-and-mortar network (which is composed of more than 1,700 retail stores), up from 65% in 2020, as consumer shopping patterns began to return to normal. Future growth is expected from store reformatting, digital and international channels, as well as new category expansion.
Read more on BBWI →
